A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia
Open Access
- 28 November 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 6956-6970
Abstract
Background: In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively studiedMethods: We used multi‐color flow cytometry, to prospectively measure absolute and relative numbers of CD4+ and CD8+ T‐cells and their subsets in 45 patients with indolent untreated CLL, 86 patients indicated for first‐line treatment, and 34 healthy controls. In 55 patients, we analyzed the impact of CITResults: CLL patients had a significant increase in most cell populations in comparison to controls. Progression of CLL was characterized by significantly elevated counts with the exception of a lower percentage of naïve T‐cells. After treatment, the percentage of naïve T‐cells further decreased at the expense of effector memory T‐cells (TEM). In patients with indolent CLL, higher percentages of naïve CD4+ (p = 0.0026) and naïve CD8+ (p = 0.023) T‐cells were associated with a longer time to first treatment (TTFT). The elevation of CD4+ central memory T‐cells (TCM) (p = 0.27) and TEM (p = 0.003) counts and a higher percentage of CD4+ TEM (p = 0.0047), were linked with shorter TTFT. In treated patients, increased regulatory T‐cells count was associated with shorter time to next treatment (TTNT) (p = 0.042), while higher CD4+ TCM count with shorter TTNT (p = 0.035) and shorter overall survival (p = 0.041).Conclusion: Our results indicate that naïve cell depletion and CD4+ TCM and TEM increases are detrimental to CLL patients' prognosis.Keywords
This publication has 39 references indexed in Scilit:
- The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemiaHaematologica, 2013
- A shorter time to the first treatment may be predicted by the absolute number of regulatory T‐cells in patients with Rai stage 0 chronic lymphocytic leukemiaAmerican Journal of Hematology, 2012
- Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cellsClinical and Experimental Immunology, 2011
- Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemiaCancer, 2010
- Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemiaCancer Immunology, Immunotherapy, 2010
- Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemiaLeukemia & Lymphoma, 2010
- Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: Intracellular cytokine expression and relationship with clinical outcomeOncology Reports, 2010
- Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapyLeukemia, 2010
- Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old peopleImmunity & Ageing, 2008
- Prognostic importance of T and NK‐cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 2008